DNMT1 and acute lymphoblastic leukemia: We deliberately choose to use 0.1 mg/kg of decitabine, as low‐dose decitabine is sufficient to deplete MLL‐rearranged ALL cells from DNMT1 (and thus to induce DNA demethylation), and prevents aspecific drug effects such as diminished DNA polymerase functioning [37].